^
Association details:
| Biomarker: | BTK C481 |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Jaypirca (pirtobrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
Published date:
05/12/2022
Excerpt:
Pirtobrutinib demonstrated promising efficacy in heavily pretreated CLL/SLL pts following multiple prior lines of therapy and in pts with BTK C481 mutations.
Trial ID:
Source:
Title:
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Published date:
11/04/2021
Excerpt:
Pirtobrutinib demonstrated promising efficacy in heavily pretreated CLL/SLL pts following multiple prior lines of therapy, including a covalent BTKi and a BCL2 inhibitor, and in pts with BTK C481 mutations.
DOI:
10.1182/blood-2021-147599
Trial ID:
Source:
Title:
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Published date:
03/06/2021
Excerpt:
Patients with previously treated B-cell malignancies were enrolled in a first-in-human, multicentre, open-label, phase 1/2 trial of the BTK inhibitor pirtobrutinib....The ORR was similar in CLL patients with previous covalent BTK inhibitor resistance (53 [67%] of 79), covalent BTK inhibitor intolerance (22 [52%] of 42), BTK C481-mutant (17 [71%] of 24) and BTK wild-type (43 [66%] of 65) disease.
DOI:
10.1016/S0140-6736(21)00224-5
Trial ID:
